Abstract 53P
Background
Glioblastoma is the one of most fast-growing primary brain tumor in adult and it carries the worst prognosis. Atorvastatin is an inhibitor of HMG-CoA reductase, a rate-limiting enzyme in the mevalonate pathway. Preclinical studies demonstrate encouraging anticancer activity of statins. The primary objective of the study was to evaluate the efficacy of Atorvastatin in addition to the standard therapy in patients with glioblastoma.
Methods
In this open-label, prospective, single-arm, phase II study, eligible patients received Atorvastatin in combination with standard therapy comprising radiotherapy and Temozolomide (TMZ). The primary endpoint is progression free survival (PFS) at 6 months. A minimum of 80% power required at least 32 eligible patients with planned final analysis after at least 1 year from last recruited patient.
Results
From January 2014 to December 2016, 36 evaluable patients were enrolled. Median age was 52 (20-69); 22% were ≥ 60 years of age and 62% were male. 97% of patients underwent resection. All patients have received Atorvastatin for a median of 6.2 (0.3 – 28 ) months duration, 80% of patients have discontinued this because of disease progression. At a median follow-up of 19 months, PFS-6 rate was 66% with median PFS of 7.6 months. Median overall survival was 19.9 months (4.8 – 42.5 months). Grades 3 and 4 hematological adverse events, including neutropenia and thrombocytopenia occurred in 7% and 12 % of patients respectively. On multivariate analysis, worse survival was associated in patients with baseline high LDL level (p = 0.046) and better survival was seen in patients received adjuvant TMZ (p = 0.001) and methylated tumors (p = 0.013).
Conclusions
This study did not meet its primary endpoint of PFS-6 compared to historical controls. However, this study proves the fact that high LDL level was found to be an important independent predictor of poor cancer-related outcome. Future clinical trials testing statins should aim to enroll patients with slow-growing tumors.
Clinical trial identification
clinical trial information: NCT02029573.
Editorial acknowledgement
Legal entity responsible for the study
King Fahad Medical City.
Funding
King Fahad Medical City.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract